Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Pharma
Sarepta CEO to retire, citing 'shocking and ironic twist of fate'
Ingram’s departure comes at a crossroads for Sarepta, as the unwavering conviction that defined his tenure faces major commercial uncertainty.
Angus Liu
Feb 26, 2026 11:30am
Another setback for Enspryng as Roche halts Duchenne development
Feb 23, 2026 3:40pm
PTC withdraws US approval filing for Duchenne drug Translarna
Feb 13, 2026 10:05am
Sarepta to test Elevidys with immunosuppressive regimen
Nov 25, 2025 2:19pm
FDA limits Elevidys gene therapy to ambulatory Duchenne patients
Nov 14, 2025 3:20pm
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
